CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 109 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q1 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $139,087,138 | -22.7% | 6,371,376 | +12.5% | 0.00% | -25.0% |
| Q2 2023 | $180,012,465 | +20.5% | 5,662,550 | -7.6% | 0.00% | 0.0% |
| Q1 2023 | $149,427,286 | -21.5% | 6,126,580 | +1.5% | 0.00% | -20.0% |
| Q4 2022 | $190,453,060 | +14.7% | 6,038,461 | +2.8% | 0.01% | 0.0% |
| Q3 2022 | $165,999,000 | +25.3% | 5,874,001 | +17.2% | 0.01% | +25.0% |
| Q2 2022 | $132,529,000 | -21.3% | 5,012,420 | +4.2% | 0.00% | 0.0% |
| Q1 2022 | $168,388,000 | +8.2% | 4,809,693 | +0.2% | 0.00% | 0.0% |
| Q4 2021 | $155,677,000 | +12.4% | 4,801,837 | +2.3% | 0.00% | +33.3% |
| Q3 2021 | $138,448,000 | +53.3% | 4,693,159 | +33.1% | 0.00% | +50.0% |
| Q2 2021 | $90,304,000 | +103.7% | 3,524,716 | +9.2% | 0.00% | +100.0% |
| Q1 2021 | $44,323,000 | -15.0% | 3,228,141 | +2.6% | 0.00% | -50.0% |
| Q4 2020 | $52,162,000 | – | 3,146,074 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,912,345 | 41.46% |
| Perceptive Advisors | 6,511,727 | $205,379,869 | 5.77% |
| Finepoint Capital LP | 517,287 | $16,315 | 5.28% |
| Artal Group S.A. | 1,900,000 | $59,926 | 3.34% |
| Affinity Asset Advisors, LLC | 215,000 | $6,781,100 | 2.66% |
| Rock Springs Capital Management LP | 2,506,464 | $79,053,875 | 1.90% |
| Hood River Capital Management LLC | 923,638 | $29,131,543 | 1.06% |
| Logos Global Management LP | 260,000 | $8,200,400 | 0.96% |
| Frazier Life Sciences Management, L.P. | 393,000 | $12,395,220 | 0.77% |
| FEDERATED HERMES, INC. | 2,867,451 | $90,439,405 | 0.25% |